title: Oral tryptic casein hydrolysate enhances phagocytosis by mouse peritoneal and blood phagocytic cells but fails to prevent induced inflammation.
abstract: Mouse experiments were conducted in order to find whether oral application of tryptic casein hydrolysate (TCH) results in enhancement of phagocytosing capacity of murine phagocytic cells as well as whether such application might be of use for prevention of inflammatory processes. Phagocytosing capacity of phagocytic cells of mice that received oral TCH once daily in a dose of 1.0 mg/g body weight dissolved in 0.5 ml of distilled water for five successive days was significantly higher (p < 0.05) than that of mice given equivalent volumes of distilled water, with a phagocytosing capacity enhancement index being 1.39 and 1.34 regarding peritoneal macrophages and blood phagocytic cells, respectively. Taken on the other hand, the immunostimulatory effects of oral TCH were found to be not enough to prevent mice from inflammation that was induced experimentally using acute (paw edema) and contact hypersensitivity models. A possibility for development of food protein enzymatic hydrolysates as antimicrobial immunostimulants acting through improvement of phagocytic cell functioning is discussed.
authors.affiliation: Immunomodulators Research Sector, Institute of Immunology, Vilnius University, 29 Moletu plentas, LT-08409 Vilnius, Lithuania.
authors.forename: Jurgita
authors.initials: J
authors.lastname: Kazlauskaite
authors.forename: Gediminas A
authors.initials: GA
authors.lastname: Biziulevicius
authors.forename: Vilhelmina
authors.initials: V
authors.lastname: Zukaite
authors.forename: Gene
authors.initials: G
authors.lastname: Biziuleviciene
authors.forename: Vale
authors.initials: V
authors.lastname: Miliukiene
authors.forename: Almantas
authors.initials: A
authors.lastname: Siaurys
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002351:Carrageenan; D002364:Caseins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D003877:Dermatitis, Contact / Q000503:physiopathology / Q000517:prevention & control; D004139:Dinitrofluorobenzene; D004195:Disease Models, Animal; D004487:Edema / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D007249:Inflammation / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control; D016753:Interleukin-10 / Q000097:blood; D017737:Macrophages, Peritoneal / Q000187:drug effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009000:Monocytes / Q000187:drug effects; D010586:Phagocytes / Q000187:drug effects*; D010587:Phagocytosis / Q000187:drug effects*; D014357:Trypsin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D002364:Caseins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; C475729:casein hydrolysate; D002351:Carrageenan; D004139:Dinitrofluorobenzene; D014357:Trypsin